Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20092026 | 0.81 | TYK2 (0.48) | TYK2KAT6AALDH1A1 | |
| SCHEMBL20150159 | 0.80 | HTT (0.51) | TYK2CYP19A1KAT6APOLBALDH1A1 | |
| SCHEMBL20225763 | 0.77 | TSHR (0.53) | PKMCYP19A1POLBMCOLN3ALDH1A1 | |
| SCHEMBL1225519 | 0.76 | ALDH1A1 (0.45) | PKMHSP90AA1MCOLN3ALDH1A1CYP3A4 | |
| SCHEMBL23154022 | 0.74 | HSP90AA1 (0.39) | PKMHSP90AA1KAT6AALDH1A1CYP3A4 | |
| SCHEMBL20150155 | 0.74 | HPGD (0.53) | POLBALDH1A1CYP3A4 | |
| SCHEMBL26124496 | 0.73 | HPGD (0.59) | POLBALDH1A1CYP3A4 | |
| SCHEMBL20150151 | 0.73 | ERN1 (0.45) | TYK2CYP19A1 | |
| SCHEMBL27181513 | 0.71 | MAPT (0.63) | PKMALDH1A1 | |
| SCHEMBL3545162 | 0.71 | MAPT (0.61) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885PKM 1134/4885CYP19A1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.